Steven Cohen's NVS Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 283,837 shares of Novartis AG (NVS) worth $43.36 M, representing 0.06% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 30 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in NVS, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2018, adding 1.14 M shares. Largest reduction occurred in Q2 2019, reducing 1.33 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Novartis (NVS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Novartis (NVS) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +283,837 | New Buy | 283,837 | $152.75 |
| Q3 2025 | -746,706 | Sold Out | 0 | $0.00 |
| Q2 2025 | -335,669 | Reduce 31.01% | 746,706 | $121.01 |
| Q1 2025 | +1.08 M | New Buy | 1.08 M | $111.48 |
| Q4 2023 | -181,247 | Sold Out | 0 | $0.00 |
| Q3 2023 | -725,039 | Reduce 80.00% | 181,247 | $101.86 |
| Q2 2023 | -905,061 | Reduce 49.97% | 906,286 | $100.91 |
| Q1 2023 | +1.11 M | Add 156.64% | 1.81 M | $92.00 |
| Q4 2022 | +56,100 | Add 8.63% | 705,800 | $90.72 |
| Q3 2022 | +348,500 | Add 115.70% | 649,700 | $76.01 |
| Q2 2022 | +301,200 | New Buy | 301,200 | $84.53 |
| Q1 2022 | -152,900 | Sold Out | 0 | $0.00 |
| Q4 2021 | +152,900 | New Buy | 152,900 | $87.47 |
| Q4 2020 | -794,930 | Sold Out | 0 | $0.00 |
| Q3 2020 | +794,930 | New Buy | 794,930 | $86.96 |
| Q4 2019 | -541,255 | Sold Out | 0 | $0.00 |
| Q3 2019 | +274,355 | Add 102.79% | 541,255 | $86.90 |
| Q2 2019 | -1.33 M | Reduce 83.30% | 266,900 | $91.31 |
| Q1 2019 | -133,221 | Reduce 7.70% | 1.6 M | $86.15 |
| Q4 2018 | +594,608 | Add 52.32% | 1.73 M | $76.89 |
| Q3 2018 | +1.14 M | New Buy | 1.14 M | $77.20 |
| Q2 2018 | -517,585 | Sold Out | 0 | $0.00 |
| Q1 2018 | +444,832 | Add 611.43% | 517,585 | $72.45 |
| Q4 2017 | +72,753 | New Buy | 72,753 | $75.23 |
| Q3 2017 | -129,344 | Sold Out | 0 | $0.00 |
| Q2 2017 | -619,046 | Reduce 82.72% | 129,344 | $74.79 |
| Q1 2017 | +748,390 | New Buy | 748,390 | $66.55 |
| Q4 2014 | -23,882 | Sold Out | 0 | $0.00 |
| Q3 2014 | -53,680 | Reduce 69.21% | 23,882 | $84.33 |
| Q2 2014 | +77,562 | Add 0.00% | 77,562 | $81.12 |
Steven Cohen's Novartis Investment FAQs
Steven Cohen first purchased Novartis AG (NVS) in Q2 2014, acquiring 77,562 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Novartis AG (NVS) for 30 quarters since Q2 2014.
Steven Cohen's largest addition to Novartis AG (NVS) was in Q3 2018, adding 1,136,387 shares worth $87.73 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 283,837 shares of Novartis AG (NVS), valued at approximately $43.36 M.
As of the Q1 2026 filing, Novartis AG (NVS) represents approximately 0.06% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Novartis AG (NVS) was 1,811,347 shares, as reported at the end of Q1 2023.